Description
Product details
TENELIGOLD PIO 20/15 Teneligliptin & Pioglitazone Introduction TENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy. Composition Teneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels. Pioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production. Mechanism of Action Teneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion. Pioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production. Indications TENELIGOLD PIO 20/15 is indicated for: Type 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications. Dosage and Administration The typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals. Dosage adjustments may be necessary based on individual patient response and tolerability. It is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control. Side Effects Common side effects may include: Hypoglycemia (especially when used in combination with insulin or sulfonylureas) Edema (fluid retention) Weight gain Headache Nasopharyngitis (common cold) More severe side effects can include: Heart failure (especially in patients with pre-existing cardiovascular disease) Hepatic dysfunction (monitor liver function tests periodically) Bone fractures (especially in women) Precautions Heart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases. Bladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors. Liver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction. Pregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks. Drug Interactions Insulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas. Gemfibrozil: May increase Pioglitazone levels, requiring dose adjustment. CYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects. Conclusion TENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP: 7877551268, 7849827488 Order NOW
